Third Quarter 2024Robust TPV growth, up 41% YoY and 8% QoQ, driven by strong performance across various verticals and countriesRecord gross profit reaching $78M in the quarter, with net take rate stab ...
Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33.
Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...
RSV Vaccine Sales: $10 million in Q3. Full-Year Product Sales Guidance: $3 billion to $3.5 billion. International Sales: $0.6 ...
Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Benzinga on MSN7d
Moderna Posts Unexpected Q3 Profit, Driven by Cost Cuts and Strong Covid Vaccine SalesModerna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback